The TBP team has deep research and development experience in pharmaceutical products, new company startup and development, and patent law. Parts of the team have worked together for nearly forty years, and each member of the team has deep experience in his/her area of expertise.
Edward J. Handler, III, Esq.
Mr. Handler, a former senior partner and of counsel, Kenyon & Kenyon, LLP, has worked on pharmaceutical intellectual property cases over the years. He has been responsible for assembling the TBP Pharma management team and for assembling the necessary consulting, licensing and IP agreements relating to C3.
Mary Jane D. O’Connell, Ph.D., Esq
Chief Executive Officer
Dr. O’Connell holds a B.S. in biological sciences from Fordham University, M.S. in natural sciences/chemistry and Ph.D. in chemistry/immunology from Roswell Park Cancer Institute, Buffalo, NY. Dr. O’Connell received her NIH NRSA postdoctoral training in immunology and molecular biology at NY Medical College and in immunochemistry at Memorial Sloan-Kettering Cancer Center where she was associated professionally for ten years as a cancer research scientist and senior research administrator. Following her J.D. from Fordham University School of Law, she was associated with Kenyon & Kenyon, LLP in pharmaceutical patent practice. Dr. O’Connell expects her MBA and M.S. in Healthcare Leadership degrees from Cornell University Johnson Graduate School of Management and Weill Cornell Medical College in 2019, bringing her expertise to focus on commercializing C3.
Laura L. Dugan, M.D.
Dr. Dugan, the inaugural holder of the Larry L. Hillblom Chair in Geriatric Medicine at the University of California San Diego (UCSD), recently joined the faculty at Vanderbilt University Medical Center. She now directs Vanderbilt’s Division of Geriatric Medicine, a division of the Department of Medicine. She is board certified in both internal medicine and geriatrics. Dr. Dugan’s research focuses on the basic biology of nervous system aging and the role of free radical neurobiology in aging and neurodegenerative diseases. Her recent work has focused on rationally designed buckminsterfullerene derivatives as antioxidants and neuroprotective agents.
Richard G. Pellegrino, M.D., Ph.D.
Chief Scientific Officer
Dr. Pellegrino is a practicing neurologist and clinical researcher and is located in Hot Springs, Arkansas. Dr. Pellegrino has been Principal Investigator of more than 180 FDA Phase II and III clinical trials tests on past neurological and medical treatments.
John F. Bronzo, Esq.
Vice President, Business Development & Strategy
Mr. Bronzo is a pharmaceutical professional with more than 38 years of experience in corporate and tax law, business development and strategy. He previously served as General Counsel to Pfizer Animal Health, now Zoetis. Prior to joining Pfizer, he spent 8 years with the Law Firm of Cadwalader, Wickersham & Taft in New York.
Joseph E. Root, Esq.
General Counsel, Secretary and Board Member
Mr. Root is an attorney with 30 years of experience developing, protecting, and exploiting patent portfolios. He is the author of “Rules of Patent Drafting: Guidelines from Federal circuit Case Law”, published by Oxford University Press in 2011. He previously served as General Counsel to sizeable companies, both public and private.